Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities in HCC
NCT07381634Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ondansetron in immune checkpoint inhibitor-related toxicity (irAEs), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Started Apr 2026; status: recruiting.
02
Drugs
ondansetron
03
Conditions
immune checkpoint inhibitor-related toxicity (irAEs)
Beyond the preview
Go deeper on NCT07381634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381634.